FORMULATION AND OPTIMIZATION OF RAFT FORMING CHEWABLE TABLET CONTAINING LAFUTIDINE
Abstract
Lafutidine is a new histamine H2- receptor antagonist having biological half-life of 1.92 h. Due to its selective absorption from upper part of gastrointestinal tract the gastroretentive drug delivery is desired in order to enhance its bioavailability. The aim of research was to formulate chewable tablets of lafutidine along with raft forming agent, antacid and gas generating agent. Tablets were prepared by wet granulation method and evaluated for raft strength, acid neutralization capacity, weight variation, % drug content, and in vitro drug release. Various raft-forming agents were used in preliminary screening. A 32 full factorial design was used for optimization in present study. Amount of calcium carbonate and ratio of sodium alginate to pectin were used as independent variables while raft strength and acid neutralizations capacity were used as dependent variables. Batch F8 was selected as optimized formulation based on maximum raft strength and good acid neutralization capacity. Drug-excipients compatibility study showed no interaction between drug and excipients. Stability study of the optimized formulation showed that the tablets were stable at accelerated environmental conditions for 1 month. It was concluded that raft forming chewable tablets prepared using an optimum amount of sodium alginate, pectin and calcium carbonate could be an efficient dosage form in the treatment of gastro oesophageal reflux disease.
Keywords:
Acid neutralization capacity, Raft strength, Raft forming agents, Lafutidine, Sodium alginate, PectinDOI
https://doi.org/10.25004/IJPSDR.2015.070302References
2. Prajapati V, Jani G, Khutliwala T, Zala B. Review on Raft-forming system-An upcoming approach of gastro retentive drug delivery system. J. Cont. Rel. 2013; 168:151-165.
3. Sandhy V, Suneeta S, Pandma V. A novel raft-forming antacid suspension using a natural dietary fiber. Int. J. Pharma. 1997; 148:117-12.
4. Hampson F, Farndale A, Strugala V. Alginate rafts and their Characterization. Int. J. Pharma. 2005; 294:137-147.
5. Patil S, Talele G. Formulation development and in vitro & in vivo evaluation of gastro retentive floating drug delivery system of Lafutidine. Asian J. Pharma. 2013; 7(2):68-74.
6. Patil S, Talele GS. Gastroretentive mucoadhesive tablet of lafutidine for controlled release and enhanced bioavailability. Drug Delivery doi: 10.3109/10717544.2013.877099.
7. Patel M, Tabia P, Bhimani B. Formulation and evaluation of raft forming chewable tablet containing Pantoprazol Sodium. Int. J. Pharm. Res. Bio-sci. 2014; 3(2):580-597.
8. Montgomery DC. Design and analysis of experiments. Edn 5, New York: John Willey & Sons, Inc., 2000.
9. Prajapati ST, Mehta AP, Modhia IP, Patel CN. Formulation & optimization of raft-forming chewable tablets contining H2 antagonists. International Journal of Pharmaceutical Investigation 2012; 2(4):176-182.
10. Strugala V, Dettmar PW, Thomas ECM. Evaluation of an innovative over–the-counter treatment for symptoms of reflux Disease: Quick-Dissolving alginate Granules. ISRN Pharmaceutics 2012; Article ID 950162, 7 pages.
11. Parekh R, Patel P, Patel Chinmay. Development and Validation of UV Spectrophotometric method for estimation of Lafutidine in bulk and pharmaceutical dosage form. Int. J. Drug. Dev. Res. 2012; 4(1):325-329.
12. Demski S, Dodds L, Harvey D, Jolliffe I, Marshall S. Chewable formulation comprising alginate, bicarbonate and carbonate. United State Patent 20110287062.2010.
13. Cox G. Pectin pharmaceutical composition. Europian Patent 0814772.1996.
14. Mei Lan Shike Hainan. Lafutidine liposome preparation and preparing method Chinese Patent CN 102716083.2014.
15. Jiang Su Runbang. Lafutidine coate tablet and preparation method. Patent Application No:-CN 10268821, 2013.
16. Shandong Qi Publication. Lafutidine gastric-retention controlled-release composition Patent Application No: CN 10191981, 2012.
17. Hainan Wei Kang. Lafutidine composition freeze-dried powder injection. Chinese Patent CN 103550170, 2014.
18. Gillan E, Ronald P. An alginate, a pectin and an antacid, such as Sodium or Potassium bicarbonate gastrointestinal reflux disease”US Patent 20050063980 A1, 2002.
Published

